GP350 AS A NOVEL VACCINE PROTEIN CARRIER

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose of the experiment: In our first set of experiment, we immunized young adult rhesus monkeys with varying doses of PPS14-gp350 conjugate adsorbed in alum and boosted similarly on day 28 and 42. Immune monkeys generated detectable IgG anti-PPS14 and anti-gp350 titer even with lowest dose of PPS14-gp350. As a follow up of this experiment, we would like to directly compare the ability of varying doses of alum-adsorbed unconjugated or PPS14-conjugated monomeric gp350 to: a) elicit primary, secondary, and tertiary plasma IgG anti-gp350 titers and induce affinity maturation as determined by ELISA, b) induce EBV-neutralizing antibody as determined by both an in vitro B cell transformation and ELISA neutralization assay and c) prime specific CD4+ T cells as determined by an in vitro re-stimulation assay.